TurkeyTuberculosis profile
Population  2017 81 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.41 (0.37–0.46) 0.51 (0.45–0.57)
Mortality (HIV+TB only) 0.017 (0.013–0.023) 0.02 (0.02–0.03)
Incidence  (includes HIV+TB) 14 (12–16) 17 (14–19)
Incidence (HIV+TB only) 0.1 (0.088–0.12) 0.13 (0.11–0.15)
Incidence (MDR/RR-TB)** 0.6 (0.48–0.74) 0.74 (0.59–0.91)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.69 (0.67–0.72) 5.1 (4.7–5.6) 5.8 (5.3–6.4)
Males 0.76 (0.73–0.78) 7 (6.2–7.7) 7.8 (6.9–8.6)
Total 1.4 (1.4–1.5) 12 (10–14) 14 (12–16)
TB case notifications, 2017  
Total cases notified 12 046
Total new and relapse 11 821
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 71%
          - % pulmonary 66%
          - % bacteriologically confirmed among pulmonary 79%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.03 (0.03–0.04)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 65 <1%
          - on antiretroviral therapy 51 78%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  350
(310–390)
Estimated % of TB cases with MDR/RR-TB 3.3% (2.8–3.8) 14% (11–17)  
% notified tested for rifampicin resistance 48% 59% 5 916
MDR/RR-TB cases tested for resistance to second-line drugs   124
Laboratory-confirmed cases MDR/RR-TB: 252, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 208, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 87% 12 017
Previously treated cases, excluding relapse, registered in 2016 51% 179
HIV-positive TB cases registered in 2016 80% 55
MDR/RR-TB cases started on second-line treatment in 2015 68% 230
XDR-TB cases started on second-line treatment in 2015 67% 3
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-12-13 Data: www.who.int/tb/data